SpaceX is turning away customers for the rocket that flew most of 2025’s trips to orbit, and some are paying extra for the last seats

Falcon 9 flew more than 50% of nearly 330 low Earth orbit launches in 2025, and SpaceX’s reported shift away from accepting some Falcon 9 customers raises concerns about a launch-capacity gap. The article says customers are paying premiums or seeking alternatives, which may lack Falcon 9’s combination of cadence, price and proven flight record; Starship delays could deepen the risk. It argues that government contracts for competing rockets and standardized satellite designs could reduce reliance on a single provider.

Analysis

The investable issue is not simply launch share shifting; it is whether scarce, flight-proven medium-lift capacity creates a durable pricing umbrella for alternatives before Starship becomes reliable. In the near term, customers may pay more and accept redesign or schedule costs, but that does not automatically translate into earnings for competitors: capacity, qualification, cadence, and insurance approval constrain how quickly demand can migrate. Rocket Lab’s Neutron is a potential beneficiary, but until it demonstrates operational readiness and customer-compatible capacity, the market may be capitalizing an opportunity rather than cash flows.

Over 1–3 months, the key catalysts are confirmation of SpaceX’s actual Falcon 9 intake policy, competitor bookings/pricing, and Neutron milestones. Government payload allocation could anchor competing providers over a longer horizon, but procurement and qualification are not immediate fixes. SpaceX also retains substantial upside if Starship reaches reliable operations; Falcon 9 scarcity could prove transitional rather than structural. A major Starship delay would extend the supply squeeze, while a rapid cadence ramp would reverse it. Treat the article’s account as a claim to verify, not proof of a formal retirement timetable. The contrarian risk is that investors overvalue announced demand before competitors can deliver; RKLB may be a beneficiary in strategic positioning without capturing near-term launch revenue. BA is not a clean expression of this capacity thesis.

Key Decisions for Investors

• Keep RKLB on a catalyst watchlist rather than buying the headline: require evidence of Neutron schedule credibility, customer bookings, and achievable medium-lift cadence before underwriting a sustained revenue uplift. Falsify the thesis if milestones slip materially or customers continue to favor SpaceX despite the claimed squeeze.
• If verified Falcon 9 capacity restrictions persist and Neutron execution improves, consider a measured relative long RKLB versus a diversified aerospace/industrials exposure; avoid treating it as a near-term capacity substitute until flight and qualification evidence supports that view. Reassess on launch schedule, customer disclosures, and any material schedule revision.
• Avoid an outright short SPCX solely on this report. Starship success could restore or expand low-cost supply and strengthen SpaceX’s position; the bearish case requires evidence of prolonged Falcon 9 withdrawal alongside Starship delays or deteriorating customer access.
• Track realized competitor launch pricing, booking lead times, customer redesign costs, and government contract awards as the read-through to margins and demand. If access normalizes or Starship establishes reliable cadence, reduce the scarcity-premium thesis; if bottlenecks persist without alternative capacity coming online, revisit it.